This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Elevance Trades at a Bargain: Is it a Good Time to Buy ELV Stock?
by Kaibalya Pravo Dey
With a strengthening commercial business, ELV is seeing steady membership growth.
Strength Seen in Elevance Health (ELV): Can Its 3.1% Jump Turn into More Strength?
by Zacks Equity Research
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
UnitedHealth Pulls Back 11% in 3 Months: Think Twice Before Buying
by Kaibalya Pravo Dey
While UNH is pushing for a more efficient and cost-effective healthcare system, ongoing regulatory uncertainty and mounting cost pressures could keep the stock under check.
Are Options Traders Betting on a Big Move in Elevance Health (ELV) Stock?
by Zacks Equity Research
Investors need to pay close attention to Elevance Health (ELV) stock based on the movements in the options market lately.
Tenet Q4 Earnings Beat Estimates on Favorable Payer Mix
by Zacks Equity Research
THC expects net operating revenues between $20.6 billion and $21 billion in 2025.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Encompass Health Q4 Earnings Beat on Strong Discharge Growth
by Zacks Equity Research
EHC expects adjusted EPS from continuing operations in the range of $4.67-$4.96 in 2025.
Ensign Group Shares Plunge 12% Despite Q4 Earnings Beat
by Zacks Equity Research
ENSG's fourth-quarter results gain on strong contribution from the Skilled Services unit, partly offset by the escalating cost of services. It estimates 2025 adjusted EPS to be within $6.16-$6.34.
Centene Q4 Earnings Beat Estimates on Membership Growth, 2025 View Up
by Zacks Equity Research
CNC now projects premium and service revenues of $158-$160 billion in 2025.
Cigna Q4 Earnings Miss Estimates on Decline in Medical Membership
by Zacks Equity Research
CI's Q4 results reflect a decline in Individual and Family Plans customers. Management expects 2025 adjusted EPS at a minimum of $29.50, which indicates growth of at least 7.9% from the 2024 figure.
Top Analyst Reports for ServiceNow, Alibaba & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including ServiceNow, Inc. (NOW), Alibaba Group Holding Limited (BABA) and Union Pacific Corporation (UNP), as well as a micro-cap stock Natural Health Trends Corp. (NHTC).
HCA Healthcare's Q4 Earnings Beat Estimates on Strong Admissions
by Zacks Equity Research
HCA's Q4 results benefit from improved equivalent admissions and inpatient surgeries, partly offset by the impact of hurricanes and higher salaries and benefits expenses.
Elevance Health's Q4 Earnings Beat Estimates on Rising Premiums
by Zacks Equity Research
ELV's fourth-quarter results benefit from rising premiums. However, higher expenses and attrition in Medicaid membership partially offset the positives.
Is UnitedHealth a Buy After Q4 Domestic Commercial Membership Growth?
by Kaibalya Pravo Dey
UNH's Optum Health is expected to serve about 5.4 million value-based care patients in 2025.
Elevance Health (ELV) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health (ELV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 1.05% and 0.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health Q4 Countdown: Smart Move to Buy or Stick With Hold?
by Zacks Equity Research
ELV's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Unveiling Elevance Health (ELV) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Elevance Health (ELV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Healthcare Executives Bullish on 2025: But Why Are Stocks Slipping?
by Kaibalya Pravo Dey
Improving the consumer experience, engagement and trust is emerging as a top strategy for healthcare companies.
Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?
by Kaibalya Pravo Dey
ELV is reallocating resources to more profitable areas and making prudent acquisitions.
UnitedHealth Stock Down 15.9% in 3 Months: Should You Hold or Fold?
by Zubia Masood
UNH faces challenges such as rising medical costs and regulatory pressures. However, it boasts robust cash flow and consistent dividend growth.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
New Strong Sell Stocks for December 11th
by Zacks Equity Research
AVNS, BATRK and ELV have been added to the Zacks Rank #5 (Strong Sell) List on December 11, 2024.
Rising Costs, Denied Claims and a Tragedy: Health Insurers Stumble
by Kaibalya Pravo Dey
Shares of UnitedHealth, Centene, Elevance Health and CVS Health have witnessed significant declines since last Wednesday.
UnitedHealth 2025 Outlook Clouded by Heartbreaking Loss of Key Leader
by Zacks Equity Research
UNH expects 2025 operating cash flows to be within $32-$33 billion.